Abstract
Genentech will work with New York City-based Lodo Therapeutics to mine bacterial genomes for novel natural products. Deal specifics were not disclosed, but Lodo could get up to $969 million as projects progress. Lodo, which was one of C&EN’s 10 Start-ups to Watch in 2016, is based on methods developed by its cofounder, Rockefeller University chemist Sean Brady. His group searches bacterial genomes for gene clusters that encode for unique molecules with specific properties.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
